The Hematology Department of Sanya Central Hospital (The Third People's Hospital of Hainan Province) serves as the leading unit for hematology quality control in Sanya. For over 30 years, it has been dedicated to serving patients with hematological diseases in the southern Hainan region. With strong support from hospital leadership in recent years, the department has focused on talent recruitment and training, significantly advancing its specialization. Its diagnostic and treatment capabilities now rank among the top tier in the province. The department currently has 31 beds, including 2 beds in a clean ward, with an annual outpatient volume exceeding 5,000 visits and over 800 inpatient admissions. It primarily treats conditions such as leukemia, multiple myeloma, lymphoma, thrombocytopenia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and severe anemia. Equipped with a blood cell separator and laboratory, the department performs blood cell morphology tests, red blood cell lifespan measurements, and blood cell separation, enabling rapid and accurate diagnosis of common hematological diseases. These capabilities are of great significance for the timely diagnosis of acute and critical hematological conditions and the differential diagnosis of anemia-related diseases.

The department has 8 hematologists, including 1 chief physician, 2 associate chief physicians, and 3 attending physicians, with 2 holding doctoral degrees and 3 holding master's degrees. Senior staff members have extensive experience in the diagnosis and management of hematological diseases, including hematopoietic stem cell transplantation. Many medical, technical, and nursing staff have received advanced training at leading hematology centers across China. In 2020, the department was accredited as a national GCP site for drug clinical trials. Fourteen medical staff members have completed GCP training and obtained certification, enabling the department to conduct clinical trials for new hematological drugs. In 2024, the department signed a strategic cooperation agreement with the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin), and became a member of the China Hematology Alliance. Experts from Tianjin Hospital regularly visit our hospital to conduct joint specialty clinics for hematological diseases and thalassemia, as well as provide consultations and technical guidance for complex and critical cases.

Current Services and Capabilities:

(1) Malignant hematological diseases: Stratified diagnosis, treatment, efficacy monitoring, and prognosis evaluation for various acute and chronic leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes. (2) Molecular diagnosis and treatment of myeloproliferative neoplasms: Polycythemia vera, thrombocythemia, myelofibrosis, etc.

(3) Intermediate-and high-dose chemotherapy for malignant hematological diseases.

(4) Blood cell apheresis and separation.

(5) Targeted therapy for hematological tumors.

(6) Immunosuppressive therapy using ATG/ALG, cyclosporine, etc., for severe aplastic anemia.

(7) Autologous hematopoietic stem cell transplantation and immune cell therapy.

(8) Genetic diagnosis and genetic counseling for inherited hematological diseases such as thalassemia, G-6-PD deficiency, and hemophilia.